Nucleai is the tissue intelligence layer for drug development and translational research. We pair AI-driven multimodal image analysis across H&E, IHC, mIF, and spatial transcriptomics with clinical outcomes linkage, delivered through our AI-driven computational platform and expert-led analysis. The result: structured tissue intelligence built to answer the two questions that determine a therapy's path: why does it work, and which patients will benefit. We work with two groups: biopharma sponsors across oncology, immunology, and metabolic disease turning tissue into program decisions, and the spatial biology platforms and research centers generating spatial biology data.
| Website | https://nucleai.ai/ |
| Revenue | $8 million |
| Employees | 68 (42 on RocketReach) |
| Founded | 2018 |
| Address | 20 W Kinzie St, Chicago, Illinois 60654, US |
| Industry | Software Development, Business Intelligence (Bi) Software, Software Development & Design, Software |
| Keywords | Precision Medicine, Drug Development, Pharmaceutical Research, Artificial Intelligence, Biotechnology, Drug Discovery, Patient Outcomes, Machine Learning, Image Analysis, Therapeutic Development, Medical Imaging, Clinical Trials, Digital Pathology, Cancer Research, Biomarker Discovery, Genomics, Proteomics |
| Competitors | Tempus Labs, Inc., Viz.ai, SOPHiA GENETICS, Qure.ai, PathAI, Indica Labs, Proscia, Aiforia Technologies, Zebra Medical Vision Ltd, DNANUDGE +51 more (view full list) |
| SIC | SIC Code 807 Companies, SIC Code 80 Companies |
| NAICS | NAICS Code 51 Companies, NAICS Code 621 Companies, NAICS Code 6215 Companies, NAICS Code 62151 Companies, NAICS Code 62 Companies, NAICS Code 513 Companies |
Looking for a particular Nucleai employee's phone or email?
The Nucleai annual revenue was $8 million in 2026.
Avi Veidman is the CEO of Nucleai.
42 people are employed at Nucleai.
Nucleai is based in Chicago, Illinois.
The NAICS codes for Nucleai are [51, 621, 6215, 62151, 62, 513].
The SIC codes for Nucleai are [807, 80].